Standard Outcome Measures for Thymic Malignancies

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis Annemarie T. Fernandes, BA, Eric.

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposals for the T component for the Forthcoming (8th) Edition of the TNM Classification of.

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients Camilla Maria T. Sagerup, MD, Milada.

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure Jessamy A. Boyd, MD, Jessica L. Hubbs,

The Impact of Thymoma Histotype on Prognosis in a Worldwide Database

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Michelle C. Ellis, MD, Brian S. Diggs, PhD, John T. Vetto, MD, Paul H

Frank Detterbeck, MD Journal of Thoracic Oncology

Thymoma—A Clinico-Pathological Long-Term Study with Emphasis on Histology and Adjuvant Radiotherapy Dose Thomas Harnath, MD, Alexander Marx, MD, Philipp.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Thymic carcinoma outcomes and prognosis: Results of an international analysis Usman Ahmad, MD, Xiaopan Yao, PhD, Frank Detterbeck, MD, James Huang, MD,

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Clinical Outcomes and Prognosis of Recurrent Thymoma Management

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Imaging Requirements in the Practice of Pulmonary Metastasectomy

Development of the International Thymic Malignancy Interest Group International Database: An Unprecedented Resource for the Study of a Rare Group of Tumors

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Matthew J. Bott, MD, Hanghang Wang, BA, William Travis, MD, Gregory J

Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Characteristics of Thoracic Malignancies That Occur After Solid-Organ Transplantation Caroline Génébès, MD, Laurent Brouchet, MD, PhD, Nassim Kamar, MD,

Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study Seiji Niho,

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer Thomas E. Stinchcombe, MD, Harry.

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Pulmonary Resection for Metastases from Colorectal Cancer

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database Enrico Ruffini, MD, Frank Detterbeck, MD, Dirk Van.

Extended Resections for Thymic Malignancies

International Thymic Malignancies Interest Group: A Way Forward

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Follow-Up of Small (4 mm or Less) Incidentally Detected Nodules by Computed Tomography in Oncology Patients: A Retrospective Review Reginald F. Munden,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Stage III Thymic Epithelial Neoplasms are Not Homogeneous with Regard to Clinical, Pathological, and Prognostic Features Min-Woong Kang, MD, PhD, Eung-Sirk.

Epidemiology of Thymoma and Associated Malignancies

Induction Therapy For Locally Advanced Thymoma

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database Sukhmani.

Presentation transcript:

Standard Outcome Measures for Thymic Malignancies James Huang, MD, Frank C. Detterbeck, MD, Zuoheng Wang, PhD, Patrick J. Loehrer, MD Journal of Thoracic Oncology Volume 5, Issue 12, Pages 2017-2023 (December 2010) DOI: 10.1097/JTO.0b013e3181f13682 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Overall cause (A) and stage-specific (B) cause of death after resection of patients with thymoma. Results are an average of studies from 1980 to 2009 of ≥100 patients reporting this data.3 Journal of Thoracic Oncology 2010 5, 2017-2023DOI: (10.1097/JTO.0b013e3181f13682) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Specific outcomes for a stage III resected thymoma at 10 years, estimated from data regarding overall survival, cause of death, incidence of recurrence, and incidence of other cancers.3 Journal of Thoracic Oncology 2010 5, 2017-2023DOI: (10.1097/JTO.0b013e3181f13682) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Variance in actuarial survival estimates by size of cohort for (A) a 10-year study duration and (B) a 5-year study duration. The vertical bars are 95% confidence intervals for the survival estimate at 5 and 10 years, based on a standard model of exponentially decreasing survival, a constant rate of accrual of patients during the course of the study until study termination, and no loss to follow-up. MST, median survival time. Journal of Thoracic Oncology 2010 5, 2017-2023DOI: (10.1097/JTO.0b013e3181f13682) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions